Feeds

UK drugs trial hospitalises six

Intensive care for 'seriously ill' men

Security for virtualized datacentres

Six drug trial volunteers who were given an anti-inflammatory drug at a private research unit based at London's Northwick Park Hospital are in intensive care after suffering a "reaction", the BBC reports.

The six were given TGN1412 - "designed to treat conditions such as rheumatoid arthritis and leukaemia" - on Monday. Within hours they were hospitalised after suffering "an inflammatory response which affects some organs of the body", as Northwick's intensive care director Ganesh Suntharalingam put it.

Suntharalingam explained that two of the men were in a critical condition, while the remainder were "serious but showing some signs of improvement".

The girlfriend of one of the men described her 28-year-old boyfriend's face as so swollen he "looks like the Elephant Man". Myfanwy Marshall told the BBC: "His friends cannot even face seeing him. I have to stay there because I'm looking beyond all the wires and the puffiness. This is not leukaemia, this is not pneumonia, this is not something they know how to deal with."

Parexel, the firm behind the trial, said it had followed guidelines and that such cases were extremely rare. The company's Professor Herman Scholtz said: "When the adverse drug reaction occurred, the Parexel clinical pharmacology medical team responded swiftly to stop the study procedures immediately."

The drug's German-based manufacturer, TeGenero, said the reactions were "completely unexpected and did not reflect results from initial laboratory studies".

The Medicines and Healthcare products Regulatory Agency (MHRA), meanwhile, immediately withdrew the trial's authorisation and issued an international warning against testing. Its inspectors have visited the unit and are consulting the local health authority, Department of Health and police with regard to the matter.

According to the BBC, the drug had already been tested on animals and cleared for human trials. ®

Internet Security Threat Report 2014

More from The Register

next story
SECRET U.S. 'SPACE WARPLANE' set to return from SPY MISSION
Robot minishuttle X-37B returns after almost 2 years in orbit
LOHAN crash lands on CNN
Overflies Die Welt en route to lively US news vid
'Utter killjoy Reg hacks have NEVER BEEN LAID', writes a fan
'Shuddit, smarty pants!' Some readers reacted badly to our last Doctor Who review ...
Experts brand LOHAN's squeaky-clean box
Phytosanitary treatment renders Vulture 2 crate fit for export
Carry On Cosmonaut: Willful Child is a poor taste Star Trek parody
Cringeworthy, crude and crass jokes abound in Steven Erikson’s sci-fi debut
White LED lies: It's great, but Nobel physics prize-winning great?
How artificial lighting could offer an artificial promise
prev story

Whitepapers

Forging a new future with identity relationship management
Learn about ForgeRock's next generation IRM platform and how it is designed to empower CEOS's and enterprises to engage with consumers.
Win a year’s supply of chocolate
There is no techie angle to this competition so we're not going to pretend there is, but everyone loves chocolate so who cares.
Why cloud backup?
Combining the latest advancements in disk-based backup with secure, integrated, cloud technologies offer organizations fast and assured recovery of their critical enterprise data.
High Performance for All
While HPC is not new, it has traditionally been seen as a specialist area – is it now geared up to meet more mainstream requirements?
Saudi Petroleum chooses Tegile storage solution
A storage solution that addresses company growth and performance for business-critical applications of caseware archive and search along with other key operational systems.